Not every form of nursing home neglect leaves a mark. Families generally know to look for pressure sores, unexplained bruises, weight loss, or a fall that no one can explain. But one of the most common ways a short-staffed facility can fail a resident is also one of the hardest to see: sedating a confused or agitated resident with powerful psychiatric drugs so that he or she is easier to manage.

This practice is known as chemical restraint. When a nursing home uses antipsychotic, sedative, or other psychotropic medications to control a resident’s behavior for the convenience of staff rather than to treat a diagnosed medical condition, it generally violates federal law and the resident’s rights. In residents with dementia, these drugs carry well-documented risks of stroke, falls, aspiration pneumonia, and death.

Families often miss chemical restraint because the symptoms look like “decline.” A parent who was restless and talkative becomes quiet and sleepy. A resident who used to walk the halls now sits slumped in a wheelchair. Staff may describe the change as the resident “settling in” or “progressing” in her dementia. In some cases, the real cause is a new prescription that no one explained to the family, sometimes paired with a new psychiatric diagnosis that appeared in the chart for the first time at age 85.

This article explains what chemical restraint is, why federal regulators have made it an enforcement priority in 2025 and 2026, the warning signs families can watch for, how to check an Indiana facility’s record, and what legal options may be available when a loved one has been harmed.

What Is a Chemical Restraint?

Federal nursing home regulations define a chemical restraint as any drug that is used for discipline or staff convenience and that is not required to treat a resident’s medical symptoms. The key question is not which drug was given, but why. The same antipsychotic medication may be an appropriate treatment for one resident with a documented psychiatric illness and an unlawful restraint for another resident who was simply calling out, wandering, or resisting care.

Every nursing home that accepts Medicare or Medicaid funding, which includes virtually every facility in Indiana, must comply with the federal Requirements of Participation found at 42 C.F.R. Part 483. Several of those provisions bear directly on chemical restraint. Under 42 C.F.R. § 483.10(e)(1), every resident has the right to be free from physical or chemical restraints imposed for purposes of discipline or convenience and not required to treat the resident’s medical symptoms, and § 483.12(a)(2) separately prohibits the facility from using any chemical restraint for those purposes.

The regulations also address the medications themselves. Section 483.45(d) requires that each resident’s drug regimen be free from unnecessary drugs, meaning drugs given in excessive doses, for excessive durations, without adequate monitoring, without adequate indications for use, or in the presence of adverse consequences that indicate the dose should be reduced or stopped. Section 483.45(e) goes further for psychotropic drugs specifically. Residents who have not used psychotropic drugs generally may not be given them unless the medication is necessary to treat a specific condition that is diagnosed and documented in the clinical record. Residents who do receive them must get gradual dose reductions and behavioral interventions unless clinically contraindicated. “As needed” (PRN) psychotropic orders are generally limited to 14 days unless the prescriber documents a rationale for extending them, and PRN antipsychotic orders are limited to 14 days and cannot be renewed unless the prescriber evaluates the resident.

State surveyors enforce these rules through citations known as F-tags. In revised guidance that took effect in 2025, CMS consolidated its rules on chemical restraint and unnecessary psychotropic drugs under a single tag, F-605 (right to be free from chemical restraints). The former psychotropic tag, F-758, was retired, and F-757 (unnecessary drugs) now covers only non-psychotropic medications. The 2025 guidance also expanded the definition of “convenience” to include medication use that causes signs of sedation, such as excessive sleeping, drowsiness, withdrawal, or decreased activity, and emphasized that residents and their representatives must be informed and have the right to accept or decline a psychotropic medication before it is started or increased. These are the same tags families will see on a facility’s CMS Form 2567 deficiency report, discussed below.

In plain terms, before a nursing home gives a resident with dementia an antipsychotic, a sedative, or a similar medication, the facility generally must have a documented clinical reason, must have tried non-drug approaches first, must inform the resident or the resident’s representative, and must keep working to reduce or stop the drug. When a facility skips those steps because a resident is “difficult” and the unit is short-staffed, that conduct may meet the definition of a chemical restraint.

Why Antipsychotic Drugs Are So Dangerous for Residents With Dementia

Antipsychotic medications such as haloperidol (Haldol), risperidone (Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa), and aripiprazole (Abilify) are approved by the U.S. Food and Drug Administration to treat conditions such as schizophrenia and bipolar disorder. With one narrow exception, they are not approved to treat the agitation, confusion, wandering, or calling out that commonly accompany Alzheimer’s disease and other dementias, and use for those behaviors is “off-label.” The exception is brexpiprazole (Rexulti), which the FDA approved in May 2023 for agitation associated with dementia due to Alzheimer’s disease. Even that approval is limited to a once-daily treatment for a specific diagnosis, not “as needed” use to quiet a resident, and the drug carries the same boxed warning as the rest of its class.

The FDA has required its most serious warning on these drugs for nearly two decades. In April 2005, after reviewing placebo-controlled clinical trials, the FDA required a boxed warning on all atypical (second-generation) antipsychotics stating that elderly patients with dementia-related psychosis treated with these drugs face an increased risk of death. In June 2008, the FDA extended the same boxed warning to the older, conventional antipsychotics after concluding that they share the same risk. No antipsychotic is approved for the treatment of dementia-related psychosis, and the FDA has advised prescribers to discuss the mortality risk with patients, families, and caregivers.

The dangers are not limited to the risk of death. In elderly residents, antipsychotics and other sedating medications are generally associated with:

• Stroke and other cerebrovascular events
• Excessive sedation, which can lead to decreased eating and drinking, dehydration, and malnutrition
• Impaired swallowing and aspiration pneumonia
• Dizziness, low blood pressure, unsteady gait, and falls, including falls that result in hip fractures and head injuries
• Movement disorders such as tardive dyskinesia and parkinsonism
• Worsened confusion and accelerated cognitive and functional decline
• Immobility that increases the risk of pressure sores

Many of these harms are the very injuries that families already associate with nursing home neglect. A resident who is sedated into immobility may develop a pressure sore. A resident who is too drowsy to eat may lose weight and become dehydrated. A resident whose balance is affected by a new medication may suffer a fall. When a family investigates one of these injuries, the medication record is often where the story begins.

For these reasons, federal regulators and professional geriatric guidelines generally expect facilities to address dementia-related behaviors first with non-pharmacological approaches: identifying and treating pain, infection, constipation, or other medical causes of agitation; adjusting the resident’s environment and routine; providing consistent caregivers; and offering meaningful activity. Those approaches require staff time. Chemical restraint does not.

The Schizophrenia Diagnosis Problem: What Federal Investigators Found

Because antipsychotic overuse in nursing homes has been a recognized problem for decades, the Centers for Medicare & Medicaid Services (CMS) tracks the percentage of each facility’s long-stay residents who receive an antipsychotic drug. That figure is a publicly reported quality measure, and it affects the facility’s star rating on the Nursing Home Care Compare website.

There is an exception built into the measure. Residents who have a diagnosis of schizophrenia, Tourette’s syndrome, or Huntington’s disease are not counted. The exception exists for a legitimate reason: antipsychotics are a standard treatment for those conditions. But it also created an incentive. A nursing home that wanted to lower its reported antipsychotic rate without actually reducing the drugs it gave residents could simply add a schizophrenia diagnosis to the chart.

In March 2026, the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services released two companion reports on this issue: Nursing Homes Inappropriately Diagnosed Residents with Schizophrenia to Mask the Misuse of Antipsychotic Drugs (OEI-02-23-00201) and Nursing Homes’ Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents (OEI-02-23-00200). The OIG reviewed 40 CMS inspection reports from focused surveys conducted between 2018 and 2021. The OIG cautioned that its sample was not designed to measure how widespread these practices are, but the examples it documented illustrate how the problem can occur.

At one nursing home, the reported antipsychotic quality measure fell from more than 80 percent to 5 percent as schizophrenia diagnoses were systematically added to resident records. At another facility, at least five residents receiving antipsychotics were newly coded as having schizophrenia in a single week, with no clinician diagnosis on record. Staff at one company were instructed to apply a schizophrenia diagnosis to residents on antipsychotics who had any of more than 200 unrelated conditions, including epilepsy and attention deficit disorder.

The individual cases were equally troubling. A medical director diagnosed a 77-year-old resident with schizophrenia without ever seeing or evaluating the resident. Another medical director prescribed antipsychotics to a 91-year-old hospice patient under a schizophrenia diagnosis. One resident was placed on an antipsychotic while she had a urinary tract infection, a condition known to cause temporary delirium in the elderly, and the facility did not reevaluate her or stop the drug once the infection was known.

Schizophrenia is typically first diagnosed in a person’s late teens to early thirties. Late-onset cases do occur, but a schizophrenia diagnosis appearing for the first time in the chart of an 80- or 90-year-old nursing home resident with dementia and no psychiatric history should generally prompt questions about who made the diagnosis and on what basis.

CMS has been aware of the pattern for several years and has escalated its response. In January 2023, the agency began off-site audits of nursing homes’ resident assessment data to identify inaccurate schizophrenia coding, and announced that facilities found to have miscoded diagnoses would have their quality measure ratings downgraded to one star for six months, automatically lowering the facility’s overall star rating. According to trade press reports, CMS has contacted hundreds of facilities for these audits, and roughly half of the facilities audited in the initial round acknowledged misdiagnoses. In April 2025, CMS put revised surveyor guidance into effect that expands the instructions for citing unnecessary psychotropic drug use and the misuse of schizophrenia diagnoses to conceal it. CMS has also acknowledged that antipsychotic use is likely underreported and has moved toward using Medicare claims data, rather than facility self-reporting alone, to measure it.

The OIG’s 2026 reports recommended that CMS consider additional penalties for facilities that assign inappropriate diagnoses, expand its use of data to target oversight (including facilities under common ownership), and do more to ensure that residents and families are fully informed when antipsychotic drugs are given. That last recommendation reflects a recurring theme in the inspection reports: families frequently did not know that their loved one had been placed on an antipsychotic at all.

Warning Signs of Chemical Restraint

Chemical restraint rarely announces itself. The changes it causes are often gradual and are easy to attribute to age or illness, especially in a resident who already has dementia. Families who visit regularly are usually in the best position to notice a change, because they know what their loved one’s baseline looked like. Signs that may warrant closer attention include:

• A resident who was previously alert becomes drowsy, lethargic, or difficult to wake, particularly in the afternoon or during visits
• A noticeable “flattening” of personality, with less talking, less eye contact, or less interest in family members
• Slurred speech, drooling, a shuffling walk, tremors, or stiffness that were not present before
• New or increased falls, especially shortly after a hospitalization or a change in medications
• Rapid weight loss or reduced eating and drinking
• A new psychiatric diagnosis in the chart, such as schizophrenia, psychosis, or bipolar disorder, in a resident with no history of mental illness
• A new antipsychotic, antianxiety, or sedative medication that the family was not told about or asked to consent to
• Staff describing the resident as “much calmer” or “doing better” when the family sees a person who is simply less present

Some of these changes can have innocent explanations, and a single sign is not proof of anything. The pattern that should concern families is a cluster of these changes that follows a medication change or a period when the resident was described as “agitated,” “combative,” or “a behavior problem.” Those labels sometimes appear in the chart shortly before a sedating medication is ordered.

Families generally have the right to see their loved one’s medication records. The Medication Administration Record (MAR) lists every drug given, the dose, and the time. Physician’s orders show when a drug was started and what reason was given. Comparing those records with the resident’s diagnoses, and with the dates of any behavioral notes, can reveal whether a drug was started to treat a condition or to manage a shift.

How to Check an Indiana Nursing Home’s Record on Antipsychotic Use

Families do not have to rely on a facility’s assurances. Two public sources show how a nursing home actually performs on this issue, and both are free.

Nursing Home Care Compare. CMS’s Care Compare website lists every Medicare- and Medicaid-certified nursing home in Indiana. Under the Quality Measures section for each facility, look for the measure labeled “Percentage of long-stay residents who got an antipsychotic medication.” The site shows the facility’s rate alongside the Indiana and national averages. A rate well above the state average is a reason to ask questions. Keep in mind, as the OIG found, that a facility’s reported rate can be artificially lowered by miscoded diagnoses, so a low number is not by itself reassuring.

The CMS Form 2567 deficiency report. When state surveyors from the Indiana Department of Health inspect a facility, they document every violation on a Form 2567, which is public. Our guide to How to Read the Indiana CMS 2567 Deficiency Report explains where to find these reports and how to interpret them. For chemical restraint concerns, the citation to look for on current reports is F-605 (right to be free from chemical restraints), which since 2025 also covers unnecessary psychotropic medications. Reports from surveys before 2025 may show the same kind of problem cited under F-758 (psychotropic medications) or F-757 (unnecessary drugs). A miscoded schizophrenia diagnosis may also appear under F-641, which addresses the accuracy of resident assessments.

The narrative portion of a 2567 citation often describes exactly the kind of conduct discussed in this article: a resident started on an antipsychotic with no documented diagnosis, a diagnosis added to the record without a psychiatric evaluation, or a family representative who was never informed. Repeated citations under these tags across multiple survey cycles generally suggest a facility-wide practice rather than an isolated error.

Families can also ask the facility directly. Federal law requires nursing homes to make their most recent survey results available on request, and a facility’s unwillingness to discuss its antipsychotic rate or its approach to dementia care is itself informative.

What Families Can Do

If you suspect that a loved one is being chemically restrained, there are practical steps you can take, both to protect the resident now and to preserve information that may matter later.

Ask for the complete medication list and the reason for each drug. Request a current copy of the physician’s orders and the Medication Administration Record. For every psychotropic medication, ask what diagnosis it is treating, who made that diagnosis, when, and on what basis. If the answer is a behavior rather than a condition (“she was agitated,” “he was resisting care”), that is a red flag.

Ask whether non-drug interventions were tried first and whether a medical cause was ruled out. Pain, urinary tract infections, constipation, dehydration, and hearing or vision problems are all common and treatable causes of agitation in residents with dementia. The care plan should document what was tried before medication.

Request a care plan meeting. Residents and their representatives have the right to participate in care planning. Use the meeting to ask that the medication be reviewed by the attending physician and the consultant pharmacist, and to request a gradual dose reduction if the drug is not clearly indicated. Put the request in writing and keep a copy.

Confirm that consent was obtained. Federal regulations require that residents or their representatives be informed about their treatment and have the right to refuse it. If you hold power of attorney or are the designated representative and were never told about the medication, say so in writing.

Document what you observe. Keep a dated log of your visits, noting your loved one’s alertness, mobility, appetite, and mood, and any statements staff make about behavior or medication. Photographs and short videos taken with the resident’s consent, or the consent of the resident’s representative, can also be useful. 

Involve the Long-Term Care Ombudsman. Indiana’s Long-Term Care Ombudsman program is a free, independent advocate for residents. Ombudsmen can attend care plan meetings, review records with your permission, and press the facility to respond. Our article on the role of the ombudsman in nursing home complaints explains how to reach them.

File a complaint with the Indiana Department of Health. The IDOH is required to investigate complaints of nursing home abuse and neglect, and chemical restraint is squarely within that definition. Our guide to filing a nursing home complaint in Indiana walks through the process. A substantiated complaint may result in a citation on the facility’s 2567.

Consult an attorney if harm has occurred. If your loved one suffered a fall, a fracture, a stroke, aspiration pneumonia, a pressure sore, severe weight loss, or died after being placed on sedating medication, it is generally advisable to speak with an attorney experienced in Indiana nursing home neglect cases as soon as possible, both because of the deadlines that may apply and because medical records and staffing data become harder to obtain over time.

Legal Accountability for Chemical Restraint in Indiana

A nursing home that chemically restrains a resident may breach both the federal standards of care described above and its duty under Indiana law to provide reasonable care. When that breach causes injury, the resident, or the resident’s family in the event of death, may be able to pursue a civil claim against the facility and, in some cases, its owners, operators, and the prescribing providers.

Chemical restraint cases typically rest on a negligence theory: the facility administered unnecessary or excessive psychotropic medication, failed to attempt non-drug interventions, failed to monitor for adverse effects, or failed to pursue gradual dose reductions. The federal nursing home regulations generally do not create a separate right to sue on their own, but evidence that a facility violated them, including the resident’s rights to be free from restraints and to be informed of and consent to treatment, can help show that the facility’s care fell below the required standard. Where a diagnosis was added to justify a medication after the fact or without a clinical evaluation, that evidence can be significant. And where a fall, stroke, aspiration event, or other complication of the medication contributed to a resident’s death, the family may be able to bring a wrongful death claim.

The facility’s own records are frequently the most important evidence. Physician’s orders, pharmacy consultant reviews, nursing notes, behavior monitoring sheets, Minimum Data Set (MDS) assessments, and the dates on which diagnoses were added to the chart can establish the sequence of events. State survey findings on the Form 2567, particularly citations under F-605 (or, for older surveys, F-757 and F-758), can corroborate that the facility’s conduct fell below the required standard. Staffing records matter as well, because chemical restraint is often associated with understaffing.

In Indiana, many nursing home neglect claims fall under the Indiana Medical Malpractice Act, which imposes specific procedural requirements, including review by a medical review panel before a lawsuit can proceed, and places limits on recoverable damages. Whether the Act applies depends on the facility’s status under the Act and the nature of the claim. Claims are also subject to strict filing deadlines, generally two years, with exceptions that can shorten or extend that period. Our article on how long you have to file a lawsuit against a nursing home in Indiana discusses these issues in more detail. Because the analysis is fact-specific, families should consult an experienced Indiana nursing home attorney promptly rather than attempting to calculate the deadline on their own.

Families should also review the admission agreement. Some facilities attempt to include arbitration clauses or shortened claim deadlines in their admission paperwork. As discussed in our article on how nursing homes exploit patients through admission agreements, these provisions may not be enforceable, but they should be identified early.

Frequently Asked Questions

Q: Is it illegal for a nursing home to give my mother an antipsychotic?

A: Not necessarily. Antipsychotics can be appropriate when a resident has a documented condition that the drug is used to treat, or in limited circumstances when a resident’s symptoms present a danger and other approaches have failed. What federal law prohibits is using these drugs for discipline or staff convenience, without a documented clinical indication, without trying non-drug approaches, without informing the resident or representative, or without ongoing efforts to reduce the dose. The question is generally whether the facility followed those requirements, not whether the drug was given at all.

Q: My father was never diagnosed with a mental illness, but his nursing home chart now says he has schizophrenia. What should I do?

A: Ask the facility, in writing, who made the diagnosis, when, and on what clinical basis, and request a copy of any psychiatric evaluation. Schizophrenia is rarely first diagnosed in late life, and federal investigators have documented facilities adding the diagnosis specifically to justify antipsychotic use. If the facility cannot produce a legitimate evaluation, raise the issue with the ombudsman and consider filing a complaint with the Indiana Department of Health. If your father has been harmed, consult an attorney.

Q: Does the nursing home have to tell me before starting a psychotropic medication?

A: Residents have the right to be informed of their treatment and to refuse it, and that right extends to the resident’s legal representative when the resident lacks capacity. CMS’s 2025 surveyor guidance specifically emphasizes that residents and representatives must be informed and given the opportunity to accept or decline before a psychotropic medication is started or its dose is increased. If you are the resident’s representative and were not informed, document that fact and raise it with the facility and the ombudsman.

Q: My mother fell and broke her hip two weeks after being started on a sedative. Could the medication be responsible?

A: It may be. Sedating medications are a well-recognized fall risk in elderly residents, and a fall that closely follows a new psychotropic prescription is a pattern that warrants investigation. An attorney can obtain the medication records, fall risk assessments, and incident reports needed to evaluate whether the facility’s medication practices contributed to the injury.

Holding Facilities Accountable

Chemical restraint can be tempting for a short-staffed facility because it takes less staff time than individualized dementia care, and it is harder for families to detect than a bruise or a bedsore. Federal regulators have made clear in 2025 and 2026 that they consider the practice, and the diagnostic coding used to hide it, a serious concern. Families who know what to look for, ask the right questions, and insist on seeing the records can play an important role in protecting their loved ones.

The Powless Law Firm represents nursing home residents and their families throughout Indiana in cases involving neglect, abuse, and wrongful death. If you believe a loved one has been harmed by inappropriate medication in a nursing home, please contact us at 877-769-5377 for a free consultation.

The content of this article is for informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship. If you have questions about a specific situation, please consult an attorney.